Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.
Mesothelioma News | 2007
Vinflunine Shown to Improve Response and Survival in Mesothelioma
A novel microtubule inhibitor, high-dose vinflunine, is yielding encouraging response and survival rates in patients with malignant pleural mesothelioma.
Pemetrexed Shows Promise in Treating Peritoneal Mesothelioma: Presented at ECCO
Pemetrexed, used alone or in tandem with a platinum agent, shows good response and disease control rates in patients diagnosed with peritoneal mesothelioma.
Eli Lilly Seeks European Approval of Alimta
Eli Lilly is filing for European approval of its Alimta Injection drug as an initial treatment for non-small cell lung cancer.
Eli Lilly & Co. Data Affirm Benefits of Using Alimta
Eli Lily says that data from two large, open- label studies show patients experienced one-year survival rates above fifty percent when treated with Alimta.
Asbestos Evidentiary Ruling Goes Against W.R. Grace
A narrow victory was won by federal prosecutors yesterday in their pursuit of W.R. Grace on criminal charges that the company released dangerous asbestos fibers throughout a mining town.
Recent Cancer Deaths Renew Fears About Mesothelioma
More than 58 former Iron Range miners have recently been diagnosed with mesothelioma according to latest information released by the Minnesota Department of Health.
Overexpressed Protein is Prevalent in Mesothelioma Cells: Recent study uncovers links to targeted therapies
A recent published study shows, for the first time, a connection between malignant mesothelioma and the overexpression of a particular genetic protein.
Armstrong World Industries Forms Asbestos Trust
The Armstrong World Industries Asbestos Trust is operational and accepting claims for those individuals that have been diagnosed with malignant mesothelioma due to asbestos exposure. Early, Ludwick, Sweeney & Strauss is currently filing claims with the trust on behalf of claimants.
